Patents Assigned to Silence Therapeutics Aktiengesellschaft (AG)
  • Interfering RNA molecules
    Patent number: 8933215
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: January 13, 2015
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Interfering RNA molecules
    Patent number: 8324370
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: December 4, 2012
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • FURTHER USE OF PROTEIN KINASE N BETA
    Publication number: 20120171220
    Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
    Type: Application
    Filed: February 9, 2012
    Publication date: July 5, 2012
    Applicant: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: ANKE KLIPPEL-GIESE, Jörg Kaufmann
  • Interfering RNA molecules
    Patent number: 7893245
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: February 22, 2011
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Further use of protein kinase N beta
    Patent number: 7713943
    Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: May 11, 2010
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Anke Klippel-Giese, Jörg Kaufmann
  • Interfering RNA molecules
    Patent number: 7452987
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: November 18, 2008
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese